Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

MLA

Schrader J, et al. “Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES).” Stroke (00392499), vol. 36, no. 6, June 2005, pp. 1218–24. EBSCOhost, https://doi.org/10.1161/01.str.0000166048.35740.a9.

APA

Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, Moses, M. A. S. E. C. with N. for S. P. S. G., Schrader, J., Lüders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J., Zidek, W., Dominiak, P., Diener, H. C., & MOSES Study Group. (2005). Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (00392499), 36(6), 1218–1224. https://doi.org/10.1161/01.str.0000166048.35740.a9

Chicago

Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, et al. 2005. “Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES).” Stroke (00392499) 36 (6): 1218–24. doi:10.1161/01.str.0000166048.35740.a9.